Netherlands-based MLA Diagnostics, a company focused on enhancing personalised treatments for skin cancer patients, has secured fresh funding to advance its
TEPMETKO is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping,